NCT05460273 · OUTCOME

Confirmed Objective Response Rate(ORR) Assessed by Independent Central Review(ICR)

A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) · Source last updated 2026-08-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Percentage of participants
Interval / dispersion: 95% Confidence Interval
Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

What was measured

Confirmed ORR is defined as the proportion of participants in each cohort who have a confirmed CR or confirmed PR, as assessed by ICR per RECIST 1.1.

Analysis population: RES: Enrolled participants who received at least one dose of study intervention and had measurable disease at baseline by ICR.

Groups in this outcome

TNBC Cohort

Final Analysis with DCO on 06May2024

NSCLC Cohort

Final Analysis with DCO on 27Nov2024

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
TNBC Cohort	77
NSCLC Cohort	40

Reported measurements

Source class 1

Values in Percentage of participants · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
TNBC Cohort	33.8	Not reported	23.4	45.4	Not reported
NSCLC Cohort	45.0	Not reported	29.3	61.5	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
23.4
upper Limit
45.4
value
33.8
group Id
OG001
lower Limit
29.3
upper Limit
61.5
value
45.0

denoms

counts
group Id
OG000
value
77
group Id
OG001
value
40
units
Participants

description

Confirmed ORR is defined as the proportion of participants in each cohort who have a confirmed CR or confirmed PR, as assessed by ICR per RECIST 1.1.

dispersion Type

95% Confidence Interval

groups

description
Final Analysis with DCO on 06May2024
id
OG000
title
TNBC Cohort
description
Final Analysis with DCO on 27Nov2024
id
OG001
title
NSCLC Cohort

param Type

NUMBER

population Description

RES: Enrolled participants who received at least one dose of study intervention and had measurable disease at baseline by ICR.

reporting Status

POSTED

time Frame

TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

title

Confirmed Objective Response Rate(ORR) Assessed by Independent Central Review(ICR)

type

PRIMARY

unit Of Measure

Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice